Internal Medicine, Nephrology · Napa, CA
NPI
1710093349
Since 2006
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3230 Beard Rd, Suite 1
Napa, CA, 94558
Phone (707) 253-7005
Groups this clinician bills Medicare through
Medicare paid, 2024
$322K
2,398 services
Medicare patients, 2024
774
Average age 76
Drug cost, 2024
$805K
2,168 prescriptions
Company payments, 2025
$2,760
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nagarathna G Manjappa was code 99214 (office e&m - established), 735 times for 443 patients. In total Nagarathna G Manjappa billed 2,398 services in 26 codes, and Medicare paid $322K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-01-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 735 | 443 | $105.28 | $77K |
| 99233 Hospital E&M - Subsequent | Facility | 690 | 191 | $102.59 | $71K |
| 99223 Hospital E&M - Initial | Facility | 224 | 188 | $143.29 | $32K |
| 90961 ESRD Related Services (not dialysis) | Office | 142 | 43 | $280.74 | $40K |
| 90962 ESRD Related Services (not dialysis) | Office | 127 | 42 | $187.28 | $24K |
| 99232 Hospital E&M - Subsequent | Facility | 94 | 70 | $66.26 | $6,228 |
| 90960 ESRD Related Services (not dialysis) | Office | 86 | 25 | $332.63 | $29K |
| 99213 Office E&M - Established | Office | 62 | 59 | $72.07 | $4,468 |
| 99204 Office E&M - New | Office | 46 | 46 | $140.55 | $6,465 |
| 99215 Office E&M - Established | Office | 37 | 33 | $156.77 | $5,800 |
| 99291 Critical Care E&M | Facility | 36 | 17 | $171.18 | $6,163 |
By year: 2022 $480K for 3,809 services; 2023 $440K for 3,427 services; 2024 $322K for 2,398 services.
Medicare prescription drug claims, 2024
In 2024, the drug Nagarathna G Manjappa prescribed most often to Medicare patients was Furosemide, with 183 prescriptions and refills. In total Nagarathna G Manjappa wrote 2,168 Medicare prescriptions that cost $805K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Furosemide Generic | 183 | 453 | 56 | $1,058 |
| Farxiga Dapagliflozin Propanediol | 182 | 343 | 43 | $185K |
| Nifedipine Er Nifedipine | 109 | 235 | 31 | $3,794 |
| Prosol Parenteral Amino Acid 20% No.1 | 106 | 106 | Under 11 | $20K |
| Amlodipine Besylate Generic | 105 | 311 | 38 | $725 |
| Clinolipid Fat Emulsion/Olive/Soy/Phospho | 104 | 104 | Under 11 | $32K |
| Calcitriol Generic | 99 | 199 | 29 | $1,323 |
| Allopurinol Generic | 77 | 221 | 21 | $680 |
| Veltassa Patiromer Calcium Sorbitex | 76 | 128 | 20 | $124K |
| Losartan Potassium Generic | 73 | 176 | 21 | $698 |
| Carvedilol Generic | 59 | 145 | 19 | $580 |
| Irbesartan Generic | 59 | 133 | 16 | $601 |
| Lisinopril Generic | 57 | 159 | 22 | $292 |
| Metoprolol Succinate Generic | 43 | 99 | 15 | $617 |
| Calcium Acetate Generic | 42 | 92 | 21 | $5,041 |
Brand drugs: 673 claims; generic drugs: 1,495 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nagarathna G Manjappa $2,760 ($2,760 in general payments such as food, travel and fees) from 10 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $1,740.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 5 | $1,740 |
| Amgen Inc. AMGN | 9 | $375 |
| Novartis Pharmaceuticals Corporation NVS | 8 | $265 |
| AstraZeneca UK Limited AZN | 1 | $130 |
| Mallinckrodt Hospital Products Inc. | 3 | $65.57 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 3 | $61.48 |
| Lilly USA, LLC LLY | 2 | $40.11 |
| Travere Therapeutics, Inc. TVTX | 4 | $32.02 |
| Merck Sharp & Dohme LLC MRK | 1 | $30.86 |
| OPKO Pharmaceuticals, LLC | 1 | $19.99 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.